AERIO News in brief Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial

被引：0
|
作者：
Cochereau, D.
Tredaniel, J.
机构：
来源：
ONCOLOGIE | 2013年 / 15卷 / 01期
关键词：
BEVACIZUMAB; GEMCITABINE;
D O I：
10.1007/s10269-013-2248-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：61 / 62
页数：2
相关论文
共 50 条
  • [41] Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study
    Qin, Shukui
    Chen, Zhendong
    Fang, Weijia
    Ren, Zhenggang
    Xu, Ruocai
    Ryoo, Baek-Yeol
    Meng, Zhiqiang
    Bai, Yuxian
    Chen, Xiaoming
    Liu, Xiufeng
    Xiao, Juxiang
    Ho, Gwo Fuang
    Mao, Yimin
    Ye, Xing
    Ying, Jieer
    Li, Jianfeng
    Zhong, Wen Yan
    Zhou, Yu
    Siegel, Abby B.
    Hao, Chunyi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [42] First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
    Yang, James Chih-Hsin
    Kang, Jin Hyoung
    Mok, Tony
    Ahn, Myung-Ju
    Srimuninnimit, Vichien
    Lin, Chia-Chi
    Kim, Dong-Wan
    Tsai, Chun-Ming
    Barraclough, Helen
    Altug, Sedat
    Orlando, Mauro
    Park, Keunchil
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (13) : 2219 - 2230
  • [43] Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life-Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer (ERACLE)
    Galetta, Domenico
    Pisconti, Salvatore
    Cinieri, Saverio
    Pappagallo, Giovanni Luigi
    Gebbia, Vittorio
    Borsellino, Nicola
    Maiello, Evaristo
    Rinaldi, Antonio
    Montrone, Michele
    Rizzo, Pietro
    Marzano, Nicola
    Sasso, Nicola
    Febbraro, Antonio
    Colucci, Giuseppe
    CLINICAL LUNG CANCER, 2011, 12 (06) : 402 - 406
  • [44] PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Reck, Martin
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    John, William
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 205 - 213
  • [45] Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Kostas
    Biesma, Bonne
    Leschinger, Monika Iris
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott P.
    Nguyen, Tuan S.
    Hozak, Rebecca R.
    Zimmermann, Annamaria
    Visseren-Grul, Carla
    Schuette, Wolfgang
    LUNG CANCER, 2013, 81 (03) : 428 - 434
  • [46] A randomised phase II study of pemetrexed versus pemetrexed plus erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
    Dittrich, Christian
    Papai-Szekely, Zsolt
    Vinolas, Nuria
    Sederholm, Christer
    Hartmann, Joerg T.
    Behringer, Dirk
    Kazeem, Gbenga
    Desaiah, Durisala
    Leschinger, Monika I.
    von Pawel, Joachim
    EUROPEAN JOURNAL OF CANCER, 2014, 50 (09) : 1571 - 1580
  • [47] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
    Koji Nishimoto
    Masato Karayama
    Naoki Inui
    Hideki Yasui
    Hironao Hozumi
    Yuzo Suzuki
    Kazuki Furuhashi
    Tomoyuki Fujisawa
    Noriyuki Enomoto
    Yutaro Nakamura
    Nao Inami
    Shun Matsuura
    Yusuke Kaida
    Takashi Matsui
    Kazuhiro Asada
    Hiroyuki Matsuda
    Masato Fujii
    Mikio Toyoshima
    Shiro Imokawa
    Takafumi Suda
    Medical Oncology, 2018, 35
  • [48] Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study
    Nishimoto, Koji
    Karayama, Masato
    Inui, Naoki
    Yasui, Hideki
    Hozumi, Hironao
    Suzuki, Yuzo
    Furuhashi, Kazuki
    Fujisawa, Tomoyuki
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Inami, Nao
    Matsuura, Shun
    Kaida, Yusuke
    Matsui, Takashi
    Asada, Kazuhiro
    Matsuda, Hiroyuki
    Fujii, Masato
    Toyoshima, Mikio
    Imokawa, Shiro
    Suda, Takafumi
    MEDICAL ONCOLOGY, 2018, 35 (07)
  • [49] A RANDOMIZED PHASE 2 STUDY COMPARING MAINTENANCE PEMETREXED (PEM) PLUS BEST SUPPORTIVE CARE (BSC) VERSUS BSC ALONE FOLLOWING INDUCTION TREATMENT WITH PEM-CISPLATIN (CIS) IN ADVANCED NONSQUAMOUS (NONSQ) NON-SMALL CELL LUNG CANCER (NSCLC)
    Meshref, Mohamed
    Gaafar, Rabab M.
    Shehata, Samir
    Hashem, Tarek
    Gerges, Dani Abi
    Azim, Hamdy Abdel
    El-Husseiny, Gamal
    Al-Hussein, Hamed
    Liu, Zhixin
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1263 - S1263
  • [50] TAGS, a randomized, double-blind, phase 3 study evaluating TAS-102 plus best supportive care vs placebo plus best supportive care in patients with metastatic gastric cancer refractory to standard treatments.
    Ilson, David H.
    Tabernero, Josep
    Shitara, Kohei
    Winkler, Robert
    Nasermoaddeli, Ali
    Ding, Cliff
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345